Status epilepticus (SE) is a neurological emergency that afflicts 120-160,000 Americans each year, which can cause brain damage and contribute to mortality. Approximately one third of patients in SE are refractory to current therapies. We will investigate the role of AMPA receptor plasticity in benzodiazepine resistant SE using genetically modified mice, advanced imaging and electrophysiology; and we will test a novel therapy.
In Aim 1, we propose to test whether a single seizure and SE enhance AMPAR mediated synaptic transmission in activated CA1 pyramidal neurons and the entorhinal cortex using patch clamp electrophysiology and biochemical techniques. The experiments in Aim 2 test the role of GluA1 plasticity in seizure spread and duration using global and conditional knockout mice.
In Aim 3, we test the efficacy of IEM 1460, a drug that targets modified AMPA receptors, in terminating SE. This project will provide novel insights into the mechanisms of SE initiation by repeated seizures. It will define the role of GluA1 subunit plasticity in seizure spread during benzodiazepine refractory SE; and provide the neurobiological basis for the development and use of drugs targeting calcium permeable AMPA receptors for terminating SE.
Status epilepticus is a neurological emergency consisting of prolonged seizures that can result in permanent brain injury and approximately 30-45% of patients do not respond to current treatments. This application tests the role of enhancement of excitatory AMPA receptor transmission in maintaining benzodiazepine-refractory status epilepticus. It tests a novel treatment designed to selectively target modified AMPA receptors.
Showing the most recent 10 out of 51 publications